ArticleOncotarget2014
Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- Molecular interaction of metastasis suppressor genes and tumor microenvironment in breast cancer.Exploration of targeted anti-tumor therapy · 2023Review
- Functional and Clinical Characteristics of Cell Adhesion Molecule CADM1 in Cancer.Frontiers in cell and developmental biology · 2021Review
- MiR-194 promotes hepatocellular carcinoma through negative regulation of CADM1.International journal of clinical and experimental pathology · 2020Article
- Distribution of metastasis in the brain in relation to the hippocampus: a retrospective single-center analysis of 565 metastases in 116 patients.Cancer imaging : the official publication of the International Cancer Imaging Society · 2019Article
- miR-424-5p Promotes Proliferation, Migration and Invasion of Laryngeal Squamous Cell Carcinoma.OncoTargets and therapy · 2019Article
- Expression profile of CADM1 and CADM4 in triple negative breast cancer with primary systemic therapy.Oncology letters · 2019Article
- LNMAT1 Promotes Invasion-Metastasis Cascade in Malignant Melanoma by Epigenetically Suppressing CADM1 Expression.Frontiers in oncology · 2019Article
- MicroRNA-155-3p promotes breast cancer progression through down-regulating CADM1.OncoTargets and therapy · 2019Article
- Oncogenic role of miR‑183‑5p in lung adenocarcinoma: A comprehensive study of qPCR, in vitro experiments and bioinformatic analysis.Oncology reports · 2018Article
- A survey of metastasis suppressors in Metazoa.Laboratory investigation; a journal of technical methods and pathology · 2018Review
- Decreased expression of CADM1 and CADM4 are associated with advanced stage breast cancer.Oncology letters · 2018Article
- Strong fascin expression promotes metastasis independent of its F-actin bundling activity.Oncotarget · 2017Article
- Interactions between RASA2, CADM1, HIF1AN gene polymorphisms and body fatness with breast cancer: a population-based case-control study in China.Oncotarget · 2017Article
- Clinicopathological analysis in PTCL-NOS with CADM1 expression.Virchows Archiv : an international journal of pathology · 2017Article
- DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer.Carcinogenesis · 2017Article
- A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor.Cancer science · 2017Article
- A pilot study on the prevalence of DNA palindromes in breast cancer genomes.BMC medical genomics · 2016Article
- Article
- A20 inhibits the motility of HCC cells induced by TNF-α.Oncotarget · 2016Article
- Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.BMC cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer brain metastases (BCBM) are detected with increasing incidence. In order to detect potential genes involved in BCBM, we first screened for genes down-regulated by methylation in cell lines with site-specific metastatic ability. The expression of five genes, CADM1, SPARC, RECK, TNFAIP3 and CXCL14, which were also found down-regulated in gene expression profiling analyses of BCBM tissue samples, was verified by qRT-PCR in a larger patient cohort. CADM1 was chosen for further down-stream analyses. A higher incidence of CADM1 methylation, correlating with lower expression levels, was found in BCBM as compared to primary BC. Loss of CADM1 protein expression was detected most commonly among BCBM samples as well as among primary tumors with subsequent brain relapse. The prognostic role of CADM1 expression was finally verified in four large independent breast cancer cohorts (n=2136). Loss of CADM1 protein expression was associated with disease stage, lymph node status, and tumor size in primary BC. Furthermore, all analyses revealed a significant association between loss of CADM1 and shorter survival. In multivariate analyses, survival was significantly shorter among patients with CADM1-negative tumors. Loss of CADM1 expression is an independent prognostic factor especially associated with the development of brain metastases in breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.